Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PP89 | ISIN: US53566P1093 | Ticker-Symbol: BT3
Tradegate
10.05.24
16:40 Uhr
1,050 Euro
-0,040
-3,67 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LINEAGE CELL THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
LINEAGE CELL THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0701,10010.05.
1,0701,11010.05.

Aktuelle News zur LINEAGE CELL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrEarnings call: Lineage Cell Therapeutics reports positive OpRegen trial results1
DoLineage Cell Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.44M beats by $0.08M1
DoLineage Cell Therapeutics, Inc. - 10-Q, Quarterly Report1
DoLineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update20CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical...
► Artikel lesen
29.04.Lineage Cell Therapeutics board chairman passes away5
22.03.Lineage Cell Therapeutics, Inc. - 8-K, Current Report7
08.03.Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript2
08.03.Earnings call: Lineage Cell Therapeutics reports on clinical programs1
07.03.Lineage Cell Therapeutics, Inc. - 10-K, Annual Report-
07.03.Lineage Cell Therapeutics, Inc. - 8-K, Current Report1
07.03.Lineage Cell Therapeutics: Q4 Earnings Insights2
07.03.Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update47CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical...
► Artikel lesen
06.03.Lineage Cell Therapeutics Q4 2023 Earnings Preview1
06.03.A Preview Of Lineage Cell Therapeutics' Earnings1
15.02.Lineage Cell Therapeutics, Inc. - 8-K, Current Report1
09.02.Lineage Cell Therapeutics closes $14 million direct offering at $1.04 per share2
06.02.Lineage Cell Therapeutics seals $14M share sale deal-
06.02.Lineage Cell Therapeutics looks to raise $14M through direct offering-
06.02.Lineage Cell Therapeutics, Inc. - 8-K, Current Report-
03.01.Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying3
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1